Most parents learn of HPV vaccine via DTC advertising: study

Share this article:

A majority of parents and healthcare providers of young women are aware of human papillomavirus (HPV), and most of them learned of the HPV vaccine through drug advertising, a study from the University of North Carolina (UNC) found.

Additionally, African-Americans—whom are twice as likely to die from HPV—were less exposed to HPV vaccine advertising, and less aware of the disease than whites, according to Noel Brewer, an author on the study.

“It's a mixed bag,” said Brewer. “The public has benefited from advertising—without ads, few would get the vaccine. But we want to make sure [consumers] are getting balanced information.”

Brewer acknowledged that the Centers for Disease Control has provided health information related to HPV and the HPV vaccine, but says pharmaceutical marketing has a greater reach. “It's an issue of scale. Pharma is making $360 each time the vaccine is administered,” said Brewer. “Increasingly, drug advertising will carry the day.”

Of the 83% of parents and healthcare providers who had heard of HPV, 82% were aware of the vaccine. However, 87% of whites surveyed had heard of the vaccine, compared with 68% of African-Americans. The study (abstract here), published in Cancer Epidemiology Biomarkers & Prevention, surveyed 889 caregivers of adolescent girls ages 10 to 18 years in southeastern North Carolina.

Merck's Gardasil is currently the only HPV vaccine on the market. Approved by the FDA in June 2006, the vaccine—administered in three injections over a six-month period—is indicated for females ages 9 to 26.

GlaxoSmithKline is developing Cervarix for the US market, a potental Gardasil competitor already available in Europe, and hopes to gain approval by the end of 2009. 

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...